MX2012014079A - Lipidos biodegradables para la administracion de agentes activos. - Google Patents
Lipidos biodegradables para la administracion de agentes activos.Info
- Publication number
- MX2012014079A MX2012014079A MX2012014079A MX2012014079A MX2012014079A MX 2012014079 A MX2012014079 A MX 2012014079A MX 2012014079 A MX2012014079 A MX 2012014079A MX 2012014079 A MX2012014079 A MX 2012014079A MX 2012014079 A MX2012014079 A MX 2012014079A
- Authority
- MX
- Mexico
- Prior art keywords
- lipid
- cationic
- delivery
- active agents
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/62—Quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un lípido catiónico que tiene uno o más grupos biodegradables localizados en la sección media o distal de una porción lipídica (por ejemplo, una cadena hidrofóbica) del lípido catiónico. Estos lípidos catiónicos pueden ser incorporados en una partícula de lípido para suministrar un agente activo, tal como un ácido nucleico. La invención también se refiere a partículas de lípido que comprenden un lípido neutro, un lípido capaz de reducir la agregación, un lípido catiónico de la presente invención, y opcionalmente, un esterol. La partícula de lípido además puede incluir un agente terapéutico tal como un ácido nucleico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35114610P | 2010-06-03 | 2010-06-03 | |
US201161489197P | 2011-05-23 | 2011-05-23 | |
PCT/US2011/039164 WO2011153493A2 (en) | 2010-06-03 | 2011-06-03 | Biodegradable lipids for the delivery of active agents |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012014079A true MX2012014079A (es) | 2013-04-05 |
MX341332B MX341332B (es) | 2016-08-16 |
Family
ID=45067325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012014079A MX341332B (es) | 2010-06-03 | 2011-06-03 | Lipidos biodegradables para la administracion de agentes activos. |
Country Status (14)
Country | Link |
---|---|
US (3) | US9012498B2 (es) |
EP (2) | EP2575764B1 (es) |
JP (3) | JP5893611B2 (es) |
KR (2) | KR20190039347A (es) |
CN (1) | CN103096875B (es) |
AU (5) | AU2011261247B2 (es) |
CA (1) | CA2800401C (es) |
DK (1) | DK2575764T3 (es) |
ES (1) | ES2634087T3 (es) |
IL (3) | IL300109A (es) |
MX (1) | MX341332B (es) |
NZ (1) | NZ605079A (es) |
SG (1) | SG186085A1 (es) |
WO (1) | WO2011153493A2 (es) |
Families Citing this family (189)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2711240C (en) * | 2008-01-02 | 2021-10-26 | Alnylam Pharmaceuticals, Inc. | Liver screening method |
ES2734973T3 (es) | 2009-12-01 | 2019-12-13 | Translate Bio Inc | Administración de ARNm para el aumento de proteínas y enzimas en enfermedades genéticas humanas |
CN103096875B (zh) * | 2010-06-03 | 2016-08-17 | 阿尔尼拉姆医药品有限公司 | 用于递送活性剂的生物可降解脂质 |
KR20130124308A (ko) * | 2010-10-21 | 2013-11-13 | 머크 샤프 앤드 돔 코포레이션 | 올리고뉴클레오티드 전달을 위한 신규 저분자량 양이온성 지질 |
EP2717893B1 (en) | 2011-06-08 | 2019-05-08 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
JP6305344B2 (ja) * | 2011-12-07 | 2018-04-04 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 活性作用物質の送達のための生分解性脂質 |
JP6305343B2 (ja) * | 2011-12-07 | 2018-04-04 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質 |
WO2013116126A1 (en) * | 2012-02-01 | 2013-08-08 | Merck Sharp & Dohme Corp. | Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
EP3501550A1 (en) | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
WO2013158579A1 (en) * | 2012-04-19 | 2013-10-24 | Merck Sharp & Dohme Corp. | Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
JP6561378B2 (ja) | 2012-06-08 | 2019-08-21 | トランスレイト バイオ, インコーポレイテッド | 非肺標的細胞へのmRNAの経肺送達 |
WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
WO2014008334A1 (en) | 2012-07-06 | 2014-01-09 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
EP4170031A1 (en) | 2012-10-23 | 2023-04-26 | Caris Science, Inc. | Aptamers and uses thereof |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
US20150366997A1 (en) | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
WO2014089239A1 (en) | 2012-12-07 | 2014-06-12 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
CA2895847C (en) | 2012-12-19 | 2019-01-08 | Caris Science, Inc. | Compositions and methods for aptamer screening |
EP3467108B1 (en) | 2013-03-14 | 2024-05-22 | Translate Bio, Inc. | Methods for purification of messenger rna |
IL290953B2 (en) | 2013-03-14 | 2024-01-01 | Ethris Gmbh | CFTR mRNA Assemblies and Related Methods and Uses |
EP3060258A1 (en) | 2013-10-22 | 2016-08-31 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
MX2016005237A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Terapia de acido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa. |
WO2015074085A1 (en) | 2013-11-18 | 2015-05-21 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for rna delivery |
US9365610B2 (en) * | 2013-11-18 | 2016-06-14 | Arcturus Therapeutics, Inc. | Asymmetric ionizable cationic lipid for RNA delivery |
WO2015095351A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS |
CN117402871A (zh) | 2014-04-25 | 2024-01-16 | 川斯勒佰尔公司 | 信使rna的纯化方法 |
SI3766916T1 (sl) * | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc. | Formulacije novih lipidov in lipidnih nanodelcev za dostavo nukleinskih kislin |
SG11201700828PA (en) | 2014-08-07 | 2017-03-30 | Takeda Pharmaceuticals Co | Cationic lipid |
WO2016027699A1 (ja) * | 2014-08-18 | 2016-02-25 | 日油株式会社 | 核酸送達のためのカチオン性脂質 |
AU2015364508A1 (en) | 2014-12-18 | 2017-07-06 | Alnylam Pharmaceuticals, Inc. | ReversirTM compounds |
CA2969664C (en) * | 2014-12-26 | 2022-06-21 | Eisai R&D Management Co., Ltd. | Cationic lipid |
JP6640750B2 (ja) * | 2015-01-30 | 2020-02-05 | 日油株式会社 | カチオン性脂質 |
US10221127B2 (en) * | 2015-06-29 | 2019-03-05 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US20170050945A1 (en) * | 2015-07-24 | 2017-02-23 | Insmed Incorporated | Compositions and methods for the treatment of sarcoidosis |
FI3368507T3 (fi) | 2015-10-28 | 2023-03-21 | Acuitas Therapeutics Inc | Uusia lipidejä ja lipidinanopartikkeliformulaatioita nukleiinihappojen annostelemiseksi |
WO2018081480A1 (en) | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
CN109311809B (zh) * | 2016-06-24 | 2022-04-08 | 卫材R&D管理有限公司 | 阳离子脂质 |
EP3500295A2 (en) | 2016-08-19 | 2019-06-26 | CureVac AG | Rna for cancer therapy |
CN110582304A (zh) | 2016-12-08 | 2019-12-17 | 库尔维科公司 | 用于治疗或预防肝脏疾病的rna |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
US10383952B2 (en) | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
EP3558354A1 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Lassa virus vaccine |
EP3558355A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Henipavirus vaccine |
EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
US20200085944A1 (en) | 2017-03-17 | 2020-03-19 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
BR112019015244A2 (pt) | 2017-03-24 | 2020-04-14 | Curevac Ag | ácidos nucleicos codificando proteínas associadas a crispr e usos dos mesmos |
WO2018191719A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipid delivery of therapeutic agents to adipose tissue |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
WO2018200943A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
US11015204B2 (en) | 2017-05-31 | 2021-05-25 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency RNA therapeutics |
AR112706A1 (es) | 2017-05-31 | 2019-12-04 | Ultragenyx Pharmaceutical Inc | Productos terapéuticos para la glucogenosis tipo iii |
WO2018222925A1 (en) | 2017-05-31 | 2018-12-06 | Ultragenyx Pharmaceutical Inc. | Therapeutics for phenylketonuria |
KR20200024905A (ko) | 2017-07-04 | 2020-03-09 | 큐어백 아게 | 신규 핵산 분자 |
CA3071968A1 (en) | 2017-08-04 | 2019-02-07 | Kyowa Kirin Co., Ltd. | Nucleic acid-containing lipid nanoparticle |
JP7355731B2 (ja) | 2017-08-16 | 2023-10-03 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤における使用のための脂質 |
US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
JP6826014B2 (ja) | 2017-09-13 | 2021-02-03 | 株式会社東芝 | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット |
CA3073634A1 (en) | 2017-10-19 | 2019-04-25 | Curevac Ag | Novel artificial nucleic acid molecules |
WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
RU2020117848A (ru) | 2017-11-08 | 2021-12-08 | Куревак Аг | Адаптиция последовательности phk |
CA3081553C (en) | 2017-11-17 | 2022-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
TWI801477B (zh) * | 2017-12-27 | 2023-05-11 | 日商衛材R&D企管股份有限公司 | 陽離子性脂質 |
JPWO2019131770A1 (ja) | 2017-12-27 | 2020-12-24 | 武田薬品工業株式会社 | 核酸含有脂質ナノ粒子及びその用途 |
EP3773702A2 (en) | 2018-04-05 | 2021-02-17 | CureVac AG | Novel yellow fever nucleic acid molecules for vaccination |
EP4227319A1 (en) | 2018-04-17 | 2023-08-16 | CureVac SE | Novel rsv rna molecules and compositions for vaccination |
JP7441802B2 (ja) * | 2018-05-30 | 2024-03-01 | トランスレイト バイオ, インコーポレイテッド | ビタミンカチオン性脂質 |
EP3813874A1 (en) | 2018-06-27 | 2021-05-05 | CureVac AG | Novel lassa virus rna molecules and compositions for vaccination |
JP6997862B2 (ja) | 2018-08-21 | 2022-02-10 | 株式会社東芝 | 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット |
US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
EP3853234A1 (en) | 2018-09-18 | 2021-07-28 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
WO2020061426A2 (en) | 2018-09-21 | 2020-03-26 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
EP4218722A3 (en) * | 2018-10-01 | 2023-10-11 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
CA3114699A1 (en) | 2018-10-09 | 2020-04-16 | The University Of British Columbia | Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto |
CA3115751A1 (en) | 2018-10-18 | 2020-04-23 | Takeda Pharmaceutical Company Limited | Method for activation/proliferation of t cells |
MA54385A (fr) * | 2018-12-05 | 2021-10-13 | Intellia Therapeutics Inc | Lipides aminés modifiés |
CA3122080A1 (en) | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
AU2019410737A1 (en) | 2018-12-21 | 2021-06-10 | CureVac SE | RNA for malaria vaccines |
CN113474328A (zh) | 2019-01-11 | 2021-10-01 | 爱康泰生治疗公司 | 用于脂质纳米颗粒递送活性剂的脂质 |
WO2020161342A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
ES2918001A2 (es) | 2019-08-14 | 2022-07-13 | Acuitas Therapeutics Inc | Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos |
AU2020328855A1 (en) | 2019-08-14 | 2022-03-03 | CureVac SE | RNA combinations and compositions with decreased immunostimulatory properties |
AU2020407285A1 (en) | 2019-12-20 | 2022-08-11 | CureVac SE | Lipid nanoparticles for delivery of nucleic acids |
MX2022009460A (es) | 2020-02-04 | 2022-12-16 | Curevac Ag | Vacuna contra el coronavirus. |
JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
IL296781A (en) | 2020-03-30 | 2022-11-01 | BioNTech SE | RNA compositions targeting claudin-18.2 |
TW202206097A (zh) | 2020-05-20 | 2022-02-16 | 美商旗艦先鋒創新有限責任公司 | 冠狀病毒抗原組成物及其用途 |
US20230193311A1 (en) | 2020-05-20 | 2023-06-22 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
US20230203509A1 (en) | 2020-05-29 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods relating thereto |
AU2021279312A1 (en) | 2020-05-29 | 2022-12-15 | CureVac SE | Nucleic acid based combination vaccines |
MX2022015042A (es) | 2020-05-29 | 2023-03-09 | Flagship Pioneering Innovations Vi Llc | Composiciones de trem y métodos relacionados con las mismas. |
WO2021257595A1 (en) | 2020-06-15 | 2021-12-23 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery for muscular dystrophies |
JP2023533528A (ja) | 2020-07-08 | 2023-08-03 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Hbvに対するrnaレプリコンワクチン |
KR20230051172A (ko) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | 지질 나노 입자에 사용하기 위한 양이온성 지질 |
US20230272052A1 (en) | 2020-07-31 | 2023-08-31 | CureVac SE | Nucleic acid encoded antibody mixtures |
WO2022043551A2 (en) | 2020-08-31 | 2022-03-03 | Curevac Ag | Multivalent nucleic acid based coronavirus vaccines |
IL300947A (en) | 2020-09-03 | 2023-04-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
CA3171051A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
CA3206285A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
CA3203442A1 (en) | 2020-12-28 | 2022-07-07 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
EP4087938A2 (en) | 2021-01-27 | 2022-11-16 | CureVac AG | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022168884A1 (ja) | 2021-02-04 | 2022-08-11 | 塩野義製薬株式会社 | カチオン性脂質 |
AU2022219902A1 (en) * | 2021-02-09 | 2023-08-10 | Serina Therapeutics (Al), Inc. | Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same |
JP2024511206A (ja) | 2021-03-26 | 2024-03-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
EP4312988A2 (en) | 2021-03-31 | 2024-02-07 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
CN115197079A (zh) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
US20240197633A1 (en) * | 2021-04-08 | 2024-06-20 | Xiamen Sinopeg Biotech Co., Ltd. | Pegylated lipid, liposome modified by the lipid, pharmaceutical composition containing the liposome, formulation and application thereof |
EP4319803A1 (en) | 2021-04-08 | 2024-02-14 | Vaxthera SAS | Coronavirus vaccine comprising a mosaic protein |
US20240148664A1 (en) | 2021-04-09 | 2024-05-09 | Sogo Pharmaceutical Co., Ltd. | Lipid and composition |
CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
CN115385820A (zh) * | 2021-05-09 | 2022-11-25 | 英维沃生物科技(苏州)有限公司 | 阳离子脂质及其应用 |
WO2023009547A1 (en) | 2021-07-26 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
CA3171750A1 (en) | 2021-07-30 | 2023-02-02 | Tim SONNTAG | Mrnas for treatment or prophylaxis of liver diseases |
WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
AU2022336209A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
CA3230056A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
EP4402121A1 (en) | 2021-09-14 | 2024-07-24 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
TW202328067A (zh) | 2021-09-14 | 2023-07-16 | 美商雷納嘉德醫療管理公司 | 環狀脂質及其使用方法 |
TW202330916A (zh) | 2021-09-17 | 2023-08-01 | 美商旗艦先鋒創新有限責任公司 | 用於產生環狀多核糖核苷酸之組成物和方法 |
WO2023069397A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
CA3237482A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023091490A1 (en) | 2021-11-16 | 2023-05-25 | Senda Biosciences, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
AU2022391677A1 (en) | 2021-11-22 | 2024-06-06 | Sail Biomedicines, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
AU2022397292A1 (en) | 2021-11-24 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
CA3239266A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovations Vi, Llc | Coronavirus immunogen compositions and their uses |
CA3238735A1 (en) | 2021-11-24 | 2023-06-01 | Jennifer A. Nelson | Immunogenic compositions and their uses |
TW202340460A (zh) | 2021-12-17 | 2023-10-16 | 美商旗艦先鋒創新有限責任公司 | 用於在變性條件下富集環狀rna之方法 |
CA3241488A1 (en) * | 2021-12-20 | 2023-06-29 | Beam Therapeutics Inc. | Ionizable amine lipids and lipid nanoparticles |
AU2022417517A1 (en) | 2021-12-22 | 2024-06-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
CA3241026A1 (en) | 2021-12-23 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
WO2023147090A1 (en) | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
CN114409554A (zh) * | 2022-01-27 | 2022-04-29 | 英维沃生物科技(苏州)有限公司 | 一种新型阳离子脂质化合物及其组合物和用途 |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023183616A1 (en) | 2022-03-25 | 2023-09-28 | Senda Biosciences, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
CN116354836A (zh) * | 2022-03-25 | 2023-06-30 | 深圳市新合生物医疗科技有限公司 | 阳离子脂质化合物及其制备方法和应用、以及mRNA递送*** |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
TW202409283A (zh) | 2022-05-13 | 2024-03-01 | 美商旗艦先鋒創新有限責任(Vii)公司 | 雙股dna組合物及相關方法 |
WO2023218431A1 (en) | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2023230295A1 (en) | 2022-05-25 | 2023-11-30 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
CN117263818A (zh) * | 2022-06-14 | 2023-12-22 | 杭州高田生物医药有限公司 | 阳离子脂质化合物及其制备方法和应用 |
WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
WO2024026308A2 (en) | 2022-07-29 | 2024-02-01 | Massachusetts Institute Of Technology | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE |
WO2024030856A2 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
WO2024049979A2 (en) | 2022-08-31 | 2024-03-07 | Senda Biosciences, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
CN115197431B (zh) * | 2022-09-15 | 2022-11-29 | 清华大学 | 脂质偶联完全可降解水溶性聚合物的合成及应用 |
WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024064931A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
WO2024064934A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
WO2024074634A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
WO2024102799A1 (en) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
WO2024121814A1 (en) | 2022-12-09 | 2024-06-13 | Takeda Pharmaceutical Company Limited | Modified immunomodulators |
EP4385523A1 (en) | 2022-12-14 | 2024-06-19 | Beijing Jitai Pharmaceutical Technology Co., Ltd. | Lipid-based topical injection formulations |
WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
WO2024141955A1 (en) | 2022-12-28 | 2024-07-04 | BioNTech SE | Rna compositions targeting hiv |
WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
WO2024151685A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
CH624011A5 (es) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
AU587989B2 (en) | 1984-10-16 | 1989-09-07 | Mitsubishi Chemical Corporation | DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins |
ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
AU6522486A (en) | 1985-10-04 | 1987-04-24 | Biotechnology Research Partners Limited | Recombinant apolipoproteins and methods |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
US4957773A (en) | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
US5182364A (en) | 1990-02-26 | 1993-01-26 | The Scripps Research Institute | Polypeptide analogs of apolipoprotein E |
US5473039A (en) | 1989-08-18 | 1995-12-05 | The Scripps Research Institute | Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs |
US5177189A (en) | 1989-08-18 | 1993-01-05 | The Scripps Research Institute | Polypeptide analogs of Apolipoprotein E |
US5168045A (en) | 1989-08-18 | 1992-12-01 | The Scripps Research Institute | Diagnostic systems and methods using polypeptide analogs of apolipoprotein e |
US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE4013632A1 (de) * | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
WO1993000443A1 (en) | 1991-06-26 | 1993-01-07 | Bio-Technology General Corp. | Purification of recombinant apolipoprotein e from bacteria |
SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
US6372886B1 (en) | 1992-06-23 | 2002-04-16 | Arch Development Corp. | Expression and purification of kringle domains of human apolipoprotein (a) in E. coli |
SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
RU2123492C1 (ru) * | 1993-02-19 | 1998-12-20 | Ниппон Синяку Ко., Лтд | Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция |
US5532130A (en) | 1993-07-20 | 1996-07-02 | Dyad Pharmaceutical Corporation | Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides |
US5840688A (en) | 1994-03-22 | 1998-11-24 | Research Corporation Technologies, Inc. | Eating suppressant peptides |
US5534499A (en) | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
AU3559695A (en) | 1994-09-30 | 1996-04-26 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
CA2222328C (en) | 1995-06-07 | 2012-01-10 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5672685A (en) | 1995-10-04 | 1997-09-30 | Duke University | Source of apolipoprotein E and method of isolating apolipoprotein E |
JP3563505B2 (ja) * | 1995-10-16 | 2004-09-08 | 花王株式会社 | 新規な第4級アンモニウム塩及びその製造方法、並びにそれを含有する毛髪化粧料 |
JPH09278726A (ja) * | 1996-04-11 | 1997-10-28 | Takeshi Imanishi | 新規リポソーム |
JPH09301936A (ja) * | 1996-05-09 | 1997-11-25 | Kao Corp | 新規第4級アンモニウム塩、その製造方法及びそれを含有する柔軟仕上剤並びに毛髪化粧料 |
EP1027033B1 (en) | 1997-05-14 | 2009-07-22 | The University Of British Columbia | High efficiency encapsulation of nucleic acids in lipid vesicles |
US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
AU2001247951A1 (en) * | 2000-02-07 | 2001-08-14 | Roche Diagnostics Corporation | Novel cationic amphiphiles |
DE60334618D1 (de) | 2002-06-28 | 2010-12-02 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
US20060051405A1 (en) | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
CA2611944A1 (en) * | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
CN103989633A (zh) | 2005-07-27 | 2014-08-20 | 普洛体维生物治疗公司 | 制造脂质体的***和方法 |
US8227248B2 (en) * | 2006-06-30 | 2012-07-24 | Hokkaido System Science Co., Ltd. | Composition for nucleic-acid transfection |
DK2068886T3 (da) | 2006-10-03 | 2013-11-18 | Tekmira Pharmaceuticals Corp | Lipidholdige præparater |
FR2909378B1 (fr) * | 2006-12-05 | 2012-01-13 | Biochimie Appliquee Soc | Ceramides ou pseudo-ceramides quaternises et les compositions cosmetiques en contenant |
TW201002126A (en) * | 2007-12-21 | 2010-01-01 | Du Pont | Encapsulation assembly for electronic devices |
WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
US8722082B2 (en) | 2008-11-10 | 2014-05-13 | Tekmira Pharmaceuticals Corporation | Lipids and compositions for the delivery of therapeutics |
CA3039251C (en) * | 2008-11-10 | 2024-01-09 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
CN102215820A (zh) * | 2008-11-17 | 2011-10-12 | 安龙制药公司 | 用于核酸输送***的可释放融合脂质 |
CA2751342C (en) | 2009-01-29 | 2019-05-07 | Alnylam Pharmaceuticals, Inc. | Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid |
SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
CN103096875B (zh) * | 2010-06-03 | 2016-08-17 | 阿尔尼拉姆医药品有限公司 | 用于递送活性剂的生物可降解脂质 |
JP6305344B2 (ja) * | 2011-12-07 | 2018-04-04 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | 活性作用物質の送達のための生分解性脂質 |
US10421908B2 (en) | 2016-03-08 | 2019-09-24 | Dic Corporation | Liquid crystal composition and liquid crystal display device including the same |
-
2011
- 2011-06-03 CN CN201180037927.7A patent/CN103096875B/zh active Active
- 2011-06-03 JP JP2013513394A patent/JP5893611B2/ja active Active
- 2011-06-03 SG SG2012087441A patent/SG186085A1/en unknown
- 2011-06-03 KR KR1020197009607A patent/KR20190039347A/ko not_active Application Discontinuation
- 2011-06-03 MX MX2012014079A patent/MX341332B/es active IP Right Grant
- 2011-06-03 EP EP11726579.3A patent/EP2575764B1/en active Active
- 2011-06-03 DK DK11726579.3T patent/DK2575764T3/en active
- 2011-06-03 US US13/153,200 patent/US9012498B2/en active Active
- 2011-06-03 KR KR1020137000092A patent/KR101967411B1/ko active IP Right Grant
- 2011-06-03 EP EP17000656.3A patent/EP3254672A1/en active Pending
- 2011-06-03 CA CA2800401A patent/CA2800401C/en active Active
- 2011-06-03 ES ES11726579.3T patent/ES2634087T3/es active Active
- 2011-06-03 NZ NZ605079A patent/NZ605079A/en unknown
- 2011-06-03 WO PCT/US2011/039164 patent/WO2011153493A2/en active Application Filing
- 2011-06-03 AU AU2011261247A patent/AU2011261247B2/en active Active
- 2011-06-03 IL IL300109A patent/IL300109A/en unknown
-
2012
- 2012-11-22 IL IL223207A patent/IL223207B/en active IP Right Grant
-
2015
- 2015-03-18 US US14/661,945 patent/US9682922B2/en active Active
-
2016
- 2016-02-23 JP JP2016031867A patent/JP6409011B2/ja active Active
- 2016-08-05 AU AU2016210739A patent/AU2016210739A1/en not_active Abandoned
-
2017
- 2017-05-15 US US15/595,646 patent/US10266484B2/en active Active
-
2018
- 2018-05-14 IL IL259334A patent/IL259334B2/en unknown
- 2018-05-15 AU AU2018203382A patent/AU2018203382A1/en not_active Abandoned
- 2018-09-21 JP JP2018177190A patent/JP2019011345A/ja active Pending
-
2020
- 2020-01-15 AU AU2020200286A patent/AU2020200286B2/en active Active
-
2022
- 2022-06-14 AU AU2022204146A patent/AU2022204146B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX341332B (es) | Lipidos biodegradables para la administracion de agentes activos. | |
EP4218722A3 (en) | Biodegradable lipids for the delivery of active agents | |
MX2019005287A (es) | Lipidos cationicos para suministro de acido nucleico y su preparacion. | |
WO2009149418A3 (en) | Compositions for the in vivo delivery of rnai agents | |
MX2022006512A (es) | Lipidos cationicos de trialquilo y metodos de uso de los mismos. | |
MX2021005389A (es) | Formulaciones de nanoparticulas lipidicas. | |
NZ622843A (en) | Improved lipid formulation | |
WO2011141705A8 (en) | Novel cationic lipids and methods of use thereof | |
WO2012103038A9 (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
WO2015184256A3 (en) | Biodegradable lipids for delivery of nucleic acids | |
MX2015008503A (es) | Conjugados dirigidos encapsulados en particulas y sus formulaciones. | |
WO2011133925A3 (en) | Targeted and light-activated cytosolic drug delivery | |
WO2013135359A8 (en) | Targeting aminoacid lipids | |
WO2008105773A3 (en) | System for targeted delivery of therapeutic agents | |
MX2020000984A (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
WO2012054500A3 (en) | Compositions for drug administration | |
WO2012054365A3 (en) | Novel low molecular weight cationic lipids for oligonucleotide delivery | |
MX348474B (es) | Lipidos, composiciones de lipido, y metodos de uso de los mismos. | |
NZ719345A (en) | Lipid nanoparticle compositions and methods for mrna delivery | |
ZA201108931B (en) | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and method of using the same | |
WO2011087548A3 (en) | Therapeutic compositions and methods for targeted delivery of active agents | |
IN2014MN01886A (es) | ||
WO2012006169A3 (en) | Compositions and methods for enhancement of nucleic acid delivery | |
MX360315B (es) | Composiciones farmaceuticas que comprenden un inhibidor de aromatasa. | |
WO2008070141A3 (en) | Compositions for delivery of therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |